The characteristics of patients with chronic hepatitis B in Turkey

Basit Öğe Kaydı
dc.authorscopusid56022199100
dc.authorscopusid35732412900
dc.authorscopusid6603745569
dc.authorscopusid24400817300
dc.authorscopusid23060531400
dc.authorscopusid6603029129
dc.authorscopusid7004280132
dc.contributor.authorKemal Celen, Mustafa
dc.contributor.authorTekin Koruk, Suda
dc.contributor.authorAygen, Bilgehan
dc.contributor.authorDal, Tuba
dc.contributor.authorKarabay, O?uz
dc.contributor.authorTosun, Selma
dc.contributor.authorKoksal, Iftihar
dc.date.accessioned2024-09-19T15:43:49Z
dc.date.available2024-09-19T15:43:49Z
dc.date.issued2014
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractAim To evaluate the characteristics of patients with hepatitis B virus (HBV) infection and summarize the treatment modalities. Methods By September 30, 2011 the data of 7871 HBsAg (+) patients were complied and analysed according to demographic and medical records (age, sex, laboratory tests, treatment with antiviral agents) in thirty centres of Turkey. Results Of the 7871 patients 3078 (39.1%) were females; mean (standard deviation) age was 35 (14) years, 3180 (40.4%) were HBsAg positive (+) after admission to a hospital, 1488 (18.9%) after blood donation and 967 (11.9%) were found during routine screening. The HBV prevalence among relatives of HBsAg (+) patients was 1764 (22.4%), and most frequently infected family members were siblings and mothers, 4961 (63.0%) and 2149 (27.3%), respectively). Anti-HDV was negative in 7407 94.1% of patients. Three-fourths of the patients 6383 (81.1%) were HBeAg negative (-). Mean (SD) ALT was 85.8 (266.4) U/L. Majority of patients, 5588 (71.0%) were chronic hepatitis-B patients under treatment, while 2283 (29.0%) were asymptomatic carriers without treatment and only 165 (2.1%) of patients were cirrhotic and 6612 (84.0%) of those were compensated. One-third of the patients 2983 (37.9%) were under a combined treatment, while others were under monotherapy. Lamivudine, entecavir and adefovir were the most frequently used oral therapies, used for 2583 (32.8%), 11.6% and 787 (10.0%) of patients, respectively), while 2975 (37.8%) of patients were under interferon treatment. Conclusion Hepatitis B is still a problem in our country. First task of the physicians and our state should be to prevent the development and spread of the disease with education and vaccination programs, safe blood transfusions, and control of barbers.en_US
dc.identifier.endpage98en_US
dc.identifier.issn1840-0132
dc.identifier.issue1en_US
dc.identifier.pmid24496347en_US
dc.identifier.scopus2-s2.0-84893219442en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage94en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12483/14581
dc.identifier.volume11en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherMedical Association of Zenica-Doboj Cantonen_US
dc.relation.ispartofMedicinski Glasniken_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBlood donoren_US
dc.subjectHepadnaviridae infectionsen_US
dc.subjectPrevalenceen_US
dc.titleThe characteristics of patients with chronic hepatitis B in Turkeyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu